Labcorp has agreed to acquire selected assets of BioReference Health from OPKO Health in a transaction potentially worth as much as $872 million.
Labcorp will pay $722 million in cash at closing, while OPKO could receive an additional payment of as much as $150 million depending on revenue generated by BioReference’s 4Kscore prostate-cancer test.
The transaction includes BioReference’s clinical-diagnostics, women’s-health, urology and corrections-testing operations.
Labcorp will also acquire more than 80 patient-service centers and ownership of the 4Kscore test, which is used to help assess the likelihood of aggressive prostate cancer before a biopsy.
The test generated approximately $27.1 million in revenue during 2025.
Labcorp expects the businesses being acquired to generate approximately $250 million in revenue during the first year after the transaction closes.
For OPKO, the sale represents a further concentration of its business around biopharmaceutical development.
The company said the transaction will streamline its operations and allow greater focus on its pharmaceutical portfolio, which includes the FDA-approved kidney-disease treatment Rayaldee.
OPKO shares rose approximately 20% in premarket trading following the announcement.
The transaction also continues consolidation within laboratory diagnostics, where scale can provide advantages in testing networks, logistics, data infrastructure and relationships with healthcare providers.
For Labcorp, the acquisition expands its specialty-testing footprint while adding physical patient-service locations.
The deal remains subject to regulatory clearance and other customary closing conditions. The companies have not provided an expected closing date.
Investors will now watch the regulatory review, integration plans and whether the acquired businesses deliver the approximately $250 million of first-year revenue expected by Labcorp.
